Darrell Raymond Anderson

US Patent:

6399061, Jun 4, 2002

Filed:

Jun 7, 1995

Appl. No.:

08/475815

Inventors:

Darrell R. Anderson - Escondido CA
Nabil Hanna - Rancho Santa Fe CA
Roland A. Newman - San Diego CA
Mitchell E. Reff - San Diego CA
William H. Rastetter - Rancho Santa Fe CA

Assignee:

IDEC Pharmaceutical Corporation - San Diego CA

International Classification:

A61K 39395

US Classification:

4241331, 5303873, 53038822, 53038873, 5303888, 53038885, 530867, 4241431, 4241441, 4241551, 4241531, 4241561, 4241721, 4241741

Abstract:

Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, and cooperative strategies comprising the use of chimeric anti-CD20 antibodies and radiolabeled anti-CD20 antibodies. Preferred anti-CD20 antibodies are the monoclonal anti-body secreted by ATCC Deposit No. HB11388 and the chimeric anti-CD20 antibody secreted by transfectoma TCAE8 accorded ATCC Deposit No. 69119.

US Patent:

6682734, Jan 27, 2004

Filed:

Jun 7, 1995

Appl. No.:

08/475813

Inventors:

Darrell R. Anderson - Escondido CA
Nabil Hanna - Olivenhain CA
John E. Leonard - Encinitas CA
Roland A. Newman - San Diego CA
Mitchell E. Reff - San Diego CA
William H. Rastetter - Rancho Sante Fe CA

Assignee:

IDEC Pharmaceuticals Corporation - San Diego CA

International Classification:

A61K 39395

US Classification:

4241331, 4241431, 4241441, 4241531, 4241551, 4241731, 4241741, 424 149, 424800, 424801, 4241561, 5303873, 53038822, 53038873, 5303888, 5303897, 5303913, 530809, 530867, 53038885

Abstract:

Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, and cooperative strategies comprising the use of chimeric anti-CD20 antibodies and radiolabeled anti-CD20 antibodies.

US Patent:

6709654, Mar 23, 2004

Filed:

Aug 26, 1999

Appl. No.:

09/383916

Inventors:

Darrell R. Anderson - Escondido CA 92029
Peter Brams - San Diego CA 92116
Nabil Hanna - Rancho Santa Fe CA 92067
William S. Shestowsky - San Diego CA 92109
Cheryl Heard - Encinitas CA 92024

International Classification:

A61K 39395

US Classification:

4241531, 4241301, 4241411, 4241431, 4241441, 4241541, 4241731, 5303871, 5303881, 5303882, 53038822, 5303887, 53038873, 53038875

Abstract:

The present invention relates to the identification of macaque antibodies to human B7. 1 and B7. 2 by screening of phage display libraries or monkey heterohybridomas obtained using B lymphocytes from B7. 1 and/or B7. 2 immunized monkeys. More specifically, the invention provides four monkey monoclonal antibodies 7B6, 16C10, 7C10 and 20C9 which inhibit the B7:CD28 pathway and thereby function as effective immunosuppressants. The invention further provides the complete DNA and amino acid sequences of the light and heavy chain of three primatized antibodies derived from those monkey monoclonal antibodies which bind B7. 1 and possibly B7. 2, primatized 7C10, primatized 7B6 and primatized 16C10. These primatized and monkey antibodies may be used as specific immunosuppressants, e. g. , for the treatment of autoimmune diseases and to prevent organ transplant rejection.

US Patent:

6893638, May 17, 2005

Filed:

Jan 12, 2001

Appl. No.:

09/758173

Inventors:

Darrell R. Anderson - Escondido CA, US
Peter Brams - San Diego CA, US
Nabil Hanna - Rancho Santa Fe CA, US
William S. Shestowsky - San Diego CA, US
Cheryl Heard - Encinitas CA, US

International Classification:

A61K039/395
C07K016/28

US Classification:

4241531, 4241301, 4241331, 4241381, 4241411, 4241431, 4241441, 4241551, 4241731, 4241741, 5303871, 5303873, 5303877, 5303881, 5303882, 53038822, 5303887, 53038873, 5303888

Abstract:

The present invention relates to methods for treating B cell lymphoma using CD80-specific antibodies.

US Patent:

7153508, Dec 26, 2006

Filed:

Feb 13, 2002

Appl. No.:

10/073138

Inventors:

Darrell R. Anderson - Escondido CA, US
Nabil Hanna - Olivenhain CA, US
Peter Brams - San Diego CA, US

Assignee:

Biogen Idec Inc. - Cambridge MA

International Classification:

A61K 39/395
C07K 16/28

US Classification:

4241531, 4241301, 4241331, 4241381, 4241411, 4241431, 4241441, 4241551, 4241731, 4241741, 5303871, 5303873, 5303877, 5303881, 5303882, 53038822, 5303887, 53038873, 5303888

Abstract:

The present invention relates to the identification of antibodies which are specific to human B7. 1 antigen (CD80) and which are capable of inhibiting the binding of B7. 1 to a CD28 receptor and which are not capable of inhibiting the binding of B7. 1 to a CTLA-4 receptor. Two of these antibodies, 16C10 and 7C10, significantly inhibit the production of IL-2, in spite of the existence of a second activating ligand B7. 2 (CD86). Blocking of the primary activation signal between CD28 and B7. 1 (CD80) with these antibodies while allowing the unimpaired or coincident interaction of CTLA-4 and B7. 1 and/or B7. 2 represents a combined antagonistic effect on positive co-stimulation with an agonistic effect on negative signaling. These antibodies may be used as specific immunosuppressants, e. g. , for the treatment of autoimmune diseases and to prevent organ transplant rejection.

US Patent:

7175847, Feb 13, 2007

Filed:

May 22, 2000

Appl. No.:

09/576424

Inventors:

Darrell R. Anderson - Escondido CA, US
Nabil Hanna - Rancho Santa Fe CA, US
Peter Brams - San Diego CA, US

Assignee:

Biogen Idec Inc. - Cambridge MA

International Classification:

A61K 39/395
C07K 16/28

US Classification:

4241531, 4241301, 4241331, 4241411, 4241431, 4241441, 4241731, 5303871, 5303873, 5303882, 53038822, 5303887, 53038873

Abstract:

The present invention relates to the identification of antibodies which are specific to human B7. 1 antigen (CD80) and which are capable of inhibiting the binding of B7. 1 to a CD28 receptor and which are not capable of inhibiting the binding of B7. 1 to a CTLA-4 receptor. Two of these antibodies, 16C10 and 7C10, significantly inhibit the production of IL-2, in spite of the existence of a second activating ligand B7. 2 (CD86). Blocking of the primary activation signal between CD28 and B7. 1 (CD80) with these antibodies while allowing the unimpaired or coincident interaction of CTLA-4 and B7. 1 and/or B7. 2 represents a combined antagonistic effect on positive co-stimulation with an agonistic effect on negative signalling. These antibodies, or B7. 1-binding fragments thereof, may be used for the treatment of Crohn's disease.

US Patent:

7192585, Mar 20, 2007

Filed:

May 31, 2005

Appl. No.:

11/139499

Inventors:

Darrell R. Anderson - Escondido CA, US
Nabil Hanna - Sante Fe CA, US
Peter Brams - San Diego CA, US

Assignee:

Biogen Idec Inc. - Cambridge MA

International Classification:

A61K 39/395
C07K 16/28

US Classification:

4241531, 4241301, 4241331, 4241381, 4241411, 4241431, 4241441, 4241551, 4241731, 5303871, 5303873, 5303877, 5303881, 5303882, 53038822, 5303887, 53038873

Abstract:

The present invention relates to the identification of antibodies which are specific to human B7. 1 antigen (CD80) and which are capable of inhibiting the binding of B7. 1 to a CD28 receptor and which are not capable of inhibiting the binding of B7. 1 to a CTLA-4 receptor. Two of these antibodies, 16C10 and 7C10, significantly inhibit the production of IL-2, in spite of the existence of a second activating ligand B7. 2 (GD86). Blocking of the primary activation signal between CD28 and B7. 1 (CD80) with these antibodies while allowing the unimpaired or coincident interaction of CTLA-4 and B7. 1 and/or B7. 2 represents a combined antagonistic effect on positive co-stimulation with an agonistic effect on negative signalling. These antibodies may be used as specific immunosuppressants, e. g. , for the treatment of autoimmune diseases and to prevent organ transplant rejection.

US Patent:

7323170, Jan 29, 2008

Filed:

Nov 15, 2004

Appl. No.:

10/986780

Inventors:

Darrell R. Anderson - Escondido CA, US
Peter Brams - San Diego CA, US
Nabil Hanna - Rancho Santa Fe CA, US
William S. Shestowsky - San Diego CA, US
Cheryl Heard - Encinitas CA, US

Assignee:

Biogen Idec Inc. - Cambridge MA

International Classification:

A61K 39/395
C07K 16/28

US Classification:

4241531, 4241301, 4241331, 4241381, 4241411, 4241431, 4241441, 4241551, 4241731, 5303871, 5303873, 5303881, 5303882, 53038822, 5303887

Abstract:

The present invention relates to the identification of macaque antibodies to human B7. 1 and B7. 2 by screening of phage display libraries or monkey heterohybridomas obtained using B lymphocytes from B7. 1 and/or B7. 2 immunized monkeys. More specifically, the invention provides four monkey monoclonal antibodies 7B6, 16C10, 7C10 and 20C9 which inhibit the B7:CD28 pathway and thereby function as effective immunosuppressants. The invention further provides the complete DNA and amino acid sequences of the light and heavy chain of three PRIMATIZED antibodies derived from those monkey monoclonal antibodies which bind B7. 1 and possibly B7. 2, PRIMATIZED 7C10, PRIMATIZED 7B6 and PRIMATIZED 16C10. These PRIMATIZED and monkey antibodies may be used as specific immunosuppressants, e. g. , for the treatment of autoimmune diseases and to prevent organ transplant rejection.